Biomea Fusion, Inc. (NASDAQ:BMEA) Forecasted to Earn Q1 2025 Earnings of ($0.82) Per Share

Biomea Fusion, Inc. (NASDAQ:BMEA) – Stock analysts at Capital One Financial issued their Q1 2025 earnings per share estimates for Biomea Fusion in a research note issued to investors on Friday, September 27th. Capital One Financial analyst N. Quibria forecasts that the company will post earnings of ($0.82) per share for the quarter. Capital One Financial currently has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($4.09) per share. Capital One Financial also issued estimates for Biomea Fusion’s Q2 2025 earnings at ($0.86) EPS and Q4 2025 earnings at ($0.84) EPS.

BMEA has been the subject of a number of other research reports. RODMAN&RENSHAW upgraded Biomea Fusion to a “strong-buy” rating in a research note on Thursday, September 26th. Scotiabank lifted their price objective on Biomea Fusion from $21.00 to $41.00 and gave the company a “sector outperform” rating in a research note on Friday, September 27th. Citigroup lowered their price objective on Biomea Fusion from $45.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, August 27th. Rodman & Renshaw upgraded Biomea Fusion from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Thursday, September 26th. Finally, HC Wainwright boosted their price target on Biomea Fusion from $15.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, September 27th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Biomea Fusion has an average rating of “Moderate Buy” and a consensus price target of $29.40.

Biomea Fusion Trading Down 5.9 %

Shares of NASDAQ:BMEA opened at $9.50 on Monday. The stock has a fifty day simple moving average of $7.06 and a two-hundred day simple moving average of $8.79. The stock has a market capitalization of $341.48 million, a price-to-earnings ratio of -2.66 and a beta of -0.47. Biomea Fusion has a 12-month low of $3.61 and a 12-month high of $22.74.

Biomea Fusion (NASDAQ:BMEA) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($1.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.03).

Institutional Trading of Biomea Fusion

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its position in Biomea Fusion by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,862 shares of the company’s stock valued at $103,000 after acquiring an additional 2,731 shares during the last quarter. Centaurus Financial Inc. purchased a new stake in Biomea Fusion during the fourth quarter valued at $102,000. PNC Financial Services Group Inc. purchased a new stake in Biomea Fusion during the fourth quarter valued at $116,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Biomea Fusion during the second quarter valued at $36,000. Finally, High Net Worth Advisory Group LLC purchased a new stake in Biomea Fusion during the second quarter valued at $45,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Insider Transactions at Biomea Fusion

In other news, Director Michael J.M. Hitchcock acquired 10,000 shares of Biomea Fusion stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average price of $10.06 per share, for a total transaction of $100,600.00. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at $150,900. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 27.57% of the company’s stock.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.